Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Headache
100%
Receptor Blockade
100%
Pituitary Adenylate Cyclase-activating polypeptide-38
100%
New Targets
100%
PAC1 Receptor
50%
Clinical Trials
33%
Migraine-like
33%
Migraine
33%
Migraine Treatment
33%
Inflammation
16%
Neuropeptides
16%
Neurodevelopment
16%
Calcitonin Gene-related Peptide
16%
Triptans
16%
Migraine Pathophysiology
16%
Calcitonin Receptor
16%
Nociception
16%
Prophylactic Treatment
16%
Side Effect Profile
16%
Therapeutic Implications
16%
Inducer
16%
Phase I Trial
16%
Antibody Targeting
16%
Pharmacological Targets
16%
Disabling Conditions
16%
Neuroprotection
16%
PACAP Receptors
16%
Neurovascular Disorders
16%
No Result
16%
Target Needs
16%
Potential Side Effects
16%
Anti-migraine Therapy
16%
Pharmacology, Toxicology and Pharmaceutical Science
Headache
100%
Receptor
100%
Migraine
100%
Hypophysis Adenylate Cyclase Activating Polypeptide
100%
Clinical Trial
42%
Diseases
28%
Side Effect
28%
Inflammation
14%
Pathophysiology
14%
Neuropeptide
14%
Triptan Derivative
14%
Calcitonin Gene Related Peptide
14%
Calcitonin Gene Related Peptide Receptor
14%
Vasoactive Intestinal Polypeptide
14%
Preclinical Study
14%
Neuroprotection
14%
Receptor Antibody
14%
Hypophysis Adenylate Cyclase Activating Polypeptide Receptor
14%
Neuroscience
Headache
100%
Migraine
100%
Hypophysis Adenylate Cyclase Activating Polypeptide
100%
Receptor
100%
Side Effect
28%
Neuropeptide
14%
Nerve Cell Differentiation
14%
Calcitonin Gene-Related Peptide Receptor
14%
Nociception
14%
Hypophysis Adenylate Cyclase Activating Polypeptide Receptor
14%
Vasoactive Intestinal Peptide
14%
Antimigraine
14%
Neuroprotection
14%
Receptor Antibody
14%
Calcitonin Gene-Related Peptide
14%
Calcitonin Gene Related Peptide
14%
Neurovascular Disorder
14%